We are a renowned Chinese medical service provider, promoting China's advanced medical technologies globally.
We assist international patients in accessing cutting-edge treatments like CAR-T cell therapy, offering them hope through China’s expertise.
16/05/2025
If your doctor recommends Breyanzi （Liso-cel） to you, you may consider coming to China to receive CARTEYVA.【same platform】【lower price】
Carteyva is developed by JW Therapeutics, a JV invested by Wuxi App Tech and Juno Therapeutics（a BMS company）.
Carteyva is a cost-effective alternative option, it is recommended to people who are suffering from relapsed or refractory LBCL, FL or MCL; People who are looking for treatment with Breyanzi; People with limited budget or people with limited insurance coverage.
We can help you fight against lymphoma with Chinese technologies, medical expertise and dedicated services.
23/04/2025
China's Dominance in TILs and CAR-T Cell Research
China has recently made significant strides in tumor-infiltrating lymphocyte (TILs) cell research. A notable case from Shanghai Ninth People's Hospital saw an oral cancer patient with mandibular invasion and lymph node metastases achieve a complete response (CR) after receiving Shali Biotechnology's GT201 injection combined with PD-1 inhibitors. In non-small cell lung cancer trials, GT201 achieved a 100% disease control rate among participants.
Genskey Therapeutics’ GC101 TIL also showed promise, with an objective response rate exceeding 35% for various solid tumors. In gynecological cancer studies, the IL-2-free TIL therapy combined with PD-1 achieved a 35.7% objective response rate and 71.4% disease control rate.
Technologically, China leads with innovations like GC101, the world’s first lymphodepletion- and IL-2-free TIL therapy, enhancing safety and accessibility. GT201 demonstrates superior proliferation and tumor-killing abilities compared to traditional TILs.
In CAR-T research, Chinese teams have optimized CAR structures and gene editing for better targeting.
Pricing is a major advantage. While Lovance’s Amtagvi costs $515,000 overseas, Chinese therapies like GC203 reduce costs through non-viral gene modification and simplified treatment settings, making them more affordable. With these dual strengths, China is rapidly emerging as a global leader in cancer cell therapy, offering new hope to patients worldwide.
23/04/2025
International patients can get TILs Cell Therapy for Cancer in China
Tumor-infiltrating lymphocyte (TILs) therapy is a highly promising cancer treatment method. Its principle is to collect lymphocytes infiltrating around tumor cells from the patient's own tumor biopsy tissue, and then expand and culture them in vitro, and finally reinfuse them into the patient's body to achieve the purpose of attacking tumor cells.
China has made remarkable progress in the research field of TILs cell therapy for cancer, which is on par with the level of the United States but with less cost. In terms of clinical trial projects, many cancer centers in China have launched clinical trials of TILs cell therapy and are conducting clinical recruitment for various advanced solid tumors.
In terms of indications, TILs cell immunotherapy is applicable to a variety of solid tumors, including melanoma, non-small cell lung cancer, cervical cancer, endometrial cancer, breast cancer, ovarian cancer, etc. For example, in the treatment of melanoma, Lifileucel has been approved for use in adult patients with unresectable or metastatic melanoma who have previously received PD-1 blocking antibody treatment. China research is also committed to improving the efficacy of TILs therapy for melanoma. In the treatment of non-small cell lung cancer, relevant clinical trials of TILs therapy have also achieved certain results. For example, some patients have experienced a reduction in tumor burden.
China's outstanding progress in the field of TILs cell research enables it to provide treatment services for international patients. With advanced technology, affordable cost, a professional medical team, and rich clinical research experience, China can bring new treatment hopes and choices to cancer patients around the world and play an important role on the international stage of cancer treatment.
22/04/2025
China Leads CAR-T Revolution in Autoimmune Diseases: Breakthroughs, Cost Efficiency, and Global Impact
China has emerged as a global pioneer in CAR-T cell therapy for autoimmune diseases, achieving transformative clinical outcomes while redefining cost structures through technological innovation. Here are the key advancements:
1. World-First Clinical Success with Universal CAR-T
Chinese researchers developed the first "off-the-shelf" universal CAR-T therapy using CRISPR-Cas9 gene editing to modify donor T cells. By knocking out five critical genes (HLA-A, HLA-B, CIITA, TRAC, and PD-1), this therapy avoids immune rejection and enables mass production. In clinical trials, 3 severe refractory autoimmune disease patients—including cases of immune-mediated necrotizing myopathy and systemic sclerosis—achieved complete remission within 6 months, with reversal of fibrosis and zero severe adverse events.
2. Technical Superiority: Dual-Target Precision and Safety
Dual-target design (CD19/CD20): A fourth-generation CAR-T technology selectively eliminates pathogenic B cells while preserving healthy immune function, achieving an 83% complete remission rate in systemic lupus erythematosus (SLE) trials.
3. Cost Efficiency: Democratizing Access
China’s CAR-T therapies slash costs to 1% of traditional autologous CAR-T through:
- Proprietary cell culture systems: Cuts raw material costs by 70%.
- Modularized production: Reduces manufacturing time to 7 days (vs. 3–6 weeks for autologous therapies)
- Scalability: A single donor batch serves 100 patients, enabling a projected treatment cost of $8,000–14,000—over 90% cheaper than U.S. therapies ($400,000+).
4. Global Recognition and Industrialization
- Research validation: Published in 《Cell》 and featured as a 《Science》 "2024 Breakthrough of the Year.
5. Case Studies: From Disability to Recovery
- A 57-year-old systemic sclerosis patient regained skin elasticity and mobility within days post-treatment; a 42-year-old myopathy patient restored muscle function to normal levele.
- In SLE trials, 13 patients achieved drug-free remission within 4–6 months, with disease activity scores dropping from 10.6 to 2.7.
Conclusion: Redefining Global Autoimmune Treatment
China’s CAR-T breakthroughs exemplify a dual triumph of scientific ingenuity and healthcare equity. By merging cutting-edge gene editing with scalable production, Chinese scientists are not only curing "incurable" diseases but also ensuring these therapies reach patients worldwide at unprecedented affordability. As clinical trials expand to lupus, hematologic cancers, and solid tumors, China is poised to lead the next era of precision medicine.
22/04/2025
Shanghai Achieves World's First CAR-T Therapy for Lung Squamous Cell Carcinoma: Pioneering Breakthrough in Solid Tumor Treatment
Shanghai Chest Hospital has successfully administered the world's first CAR-T cell therapy targeting lung squamous cell carcinoma, marking a milestone in solid tumor immunotherapy. The treatment was performed on a 65-year-old patient with advanced-stage disease who had exhausted traditional therapies (chemotherapy, radiotherapy, and targeted therapy). Post-treatment imaging revealed a 30% reduction in tumor size within 14 days, with significant alleviation of respiratory symptoms.
Innovative Dual-Targeting CAR-T Technology
Lung squamous cell carcinoma accounts for 30% of lung cancer cases and has a 5-year survival rate below 20% due to limited treatment options. CAR-T therapy, previously effective in blood cancers like leukemia , faces challenges in solid tumors due to antigen heterogeneity and immunosuppressive microenvironments. The Shanghai team developed a bispecific CAR-T that simultaneously targets PD-L1 (an immune checkpoint) and tumor-associated antigens. This approach not only enhances tumor-killing precision but also blocks immune evasion mechanisms.
Clinical Significance and Future Directions
Lead researcher Prof. Lu Shun emphasized, “This breakthrough addresses two core challenges in solid tumor CAR-T therapy: antigen selection and microenvironment modulation.” The ongoing Phase I trial has enrolled 12 patients, achieving a 40% objective response rate—far surpassing conventional therapies. The technology also holds promise for PD-L1-high cancers like esophageal and head-neck cancers.
Next steps include optimizing CAR-T constructs and exploring combination therapies with PD-1 inhibitors or cancer vaccines.
Shanghai’s breakthrough exemplifies China’s growing dominance in cell therapy innovation, offering a replicable model for tackling historically intractable cancers. As research expands, CAR-T’s potential to transform solid tumor treatment grows ever more tangible.
22/04/2025
Chinese Scientists Break CAR-T Therapy's "Sky-High Price" Barrier: Allogeneic Universal CAR-T Costs Reduced to Below $10,000
A breakthrough by East China Normal University (ECNU) Professor Du Bing and his team, in collaboration with Shanghai Changzheng Hospital and Zhejiang University Second Hospital, has been selected as one of the top ten domestic and international scientific news stories of 2024. This innovation not only overcomes the rejection challenges of allogeneic CAR-T cells but also slashes treatment costs to 1% of autologous CAR-T therapies, offering new hope to global patients.
Crushing the "Sky-High Price" Barrier: From Personalization to Mass Production
Traditional CAR-T therapy requires extracting a patient’s own T cells for gene editing, a personalized process that drives exorbitant costs. The first approved CAR-T product globally cost $475,000, while the lowest-priced domestic product remains at RMB 999,000 (≈$140,000). However, Du Bing’s team developed a novel gene-editing strategy targeting five critical genes in donor T cells, effectively masking the human leukocyte antigen (HLA) "identity barcode." This enables mass production of "off-the-shelf" allogeneic CAR-T cells, reducing manufacturing costs to 1% of autologous therapies. Once commercialized, this product, named TyU19, is expected to cost under RMB 100,000 (≈$14,000), marking a tenfold price reduction.
Technical Advantages: Safety and Efficacy Breakthroughs
Unlike international counterparts requiring pre-treatment immunosuppression, Du’s team’s allogeneic CAR-T cells evade immune recognition entirely, significantly lowering infection risks. Clinical trials demonstrated remarkable outcomes in severe autoimmune diseases, including immune-mediated necrotizing myopathy and systemic sclerosis. One paralyzed patient regained mobility within three months, driving complete remission in all three trial participants. Published in 《Cell》, this study represents the first global success of allogeneic CAR-T in autoimmune diseases.
Broader Applications and Industrialization Prospects
The TyU19 product has already achieved 100% complete remission in acute lymphoblastic leukemia patients. In 2025, the team plans to expand clinical trials to systemic lupus erythematosus, hematologic malignancies, and solid tumors. Collaborations with biotech firms like Shanghai Bangyao Biotechnology aim to scale production, potentially establishing a "Shanghai-made" CAR-T technology cluster. Recognized by 《Science》 magazine as a 2024 breakthrough, this innovation underscores China’s leadership in cell therapy.
Conclusion: From "Catch-Up" to "Pioneering"**
This breakthrough signifies China’s transition from follower to leader in CAR-T innovation. Chinese scientists are addressing global healthcare disparities, ensuring cutting-edge therapies benefit broader populations. As allogeneic CAR-T therapies advance, the era of "sky-high" medical costs may soon become a relic.
18/04/2025
Global Breakthrough: China's LK101 Neoantigen mRNA Vaccine Receives FDA IND Approval, Opening New Horizons for Precision Cancer Therapy
— International Patients Welcome to China to get cancer vaccine treatment
In February 2025, Beijing-based LK Life Science announced that its individualized neoantigen mRNA vaccine, LK101 Injection, became the first Chinese tumor neoantigen mRNA vaccine to receive U.S. Food and Drug Administration (FDA) approval for clinical trials (IND). This milestone underscores China's leadership in cancer immunotherapy and offers global patients access to cutting-edge treatment options.
Technological Innovation: AI-Driven Precision Medicine
LK101 leverages "AI + high-throughput sequencing" to identify tumor-specific mutations within 24 hours and design personalized vaccines. Its core advantages include:
1. Highly Individualized: Targets unique tumor mutations to activate the immune system while sparing healthy cells ;
2. Rapid Production: Proprietary processes enable swift vaccine development from antigen prediction to manufacturing, enhancing treatment timeliness ;
3. Superior Safety: Phase I clinical trials in China demonstrated excellent tolerability, no severe adverse reactions, and significant anti-tumor activity .
Global Recognition: From China to the World Stage
Prior to FDA approval, LK101 had already received IND clearance from China's National Medical Products Administration (NMPA) and completed Phase I trials. Preliminary results showed promising efficacy in advanced solid tumors . The FDA approval marks a pivotal step for Chinese biotech firms in global oncology drug competition. LK Life Science plans to initiate multi-center Phase II trials across China, the U.S., and Europe to accelerate commercialization .
International Patient Access:
With China emerging as a leader in cancer immunotherapy, Overseas patients can apply for this new treatment in China.
16/04/2025
Breakthrough in Advanced Gastric Cancer Treatment: China's Claudin18.2 CAR-T Therapy Achieves Complete Remission with Technological Leadership and Cost Benefits
A Chinese-developed Claudin18.2 CAR-T therapy (CT041) has made significant progress in treating advanced gastric cancer. An American patient with signet ring cell carcinoma, aged 30, achieved complete disappearance of tumor lesions (CR) after two infusions of CT041, with molecular residual disease (MRD) testing negative. As of July 2023 follow-up, the patient maintained complete remission.
CT041, the world's first Claudin18.2-targeted CAR-T therapy, was pioneered by Chinese researchers and approved for clinical trials in both China and the U.S. (IND). Its innovations include:
1. Precision Targeting: Genetically engineered T cells precisely recognize Claudin18.2 antigens, minimizing off-target effects;
2. Global Validation: Conducted trials at leading U.S. cancer centers like MD Anderson and Mayo Clinic, becoming the first Chinese CAR-T therapy approved by the FDA；
3. Superior Efficacy: Achieved a CR rate of 13.4% in 100% chemotherapy-resistant gastric cancer patients, surpassing conventional treatments
Cost Advantages
Compared to similar therapies in the U.S. (e.g., Novartis' CAR-T priced over $400,000), CT041's clinical trial costs are 1/3-1/2 of Western prices,. This affordability attracts global patients, particularly from developing countries.
16/04/2025
Paul Anderson, Chief Academic Officer of Mass General Brigham healthcare system: The next 20 years will be focused on gene and cell therapy, with China's innovative achievements spreading globally.
Chinese medical innovation is undergoing a transformative shift, according to Paul Anderson, Chief Academic Officer of Massachusetts General Brigham. While previously serving primarily as contract research organizations (CROs) supporting international pharmaceutical companies, Chinese enterprises are now demonstrating iterative innovation capabilities in gene editing and cell therapy. Notably, CAR-T cell therapies developed in China show significantly lower costs compared to U.S. counterparts, with some technologies advancing to clinical validation stages. Anderson specifically highlighted breakthroughs in glioblastoma treatment, emphasizing that these innovations will benefit global patients through technology licensing or product exports.
15/04/2025
Recently, a patient with relapsed lymphoma after 5th-line chemotherapy achieved complete remission for over two years through CAR-T therapy, marking one of the longest survivors following the approval of China's first commercially available CAR-T treatment. This milestone was achieved by a team led by Professor Huang Huiqiang at Sun Yat-sen University Cancer Center.
Lymphoma is a common hematologic malignancy, traditionally treated with combined chemotherapy regimens, autologous hematopoietic stem cell transplantation, targeted therapy, and immunomodulatory agents. CAR-T (Chimeric Antigen Receptor T-cell) therapy, a cutting-edge precision oncology approach, has recently transitioned from experimental to clinical practice, offering rapid and highly effective treatment outcomes.
"Diffuse large B-cell lymphoma (DLBCL), a prevalent aggressive lymphoma, is characterized by rapid progression, high mortality, and short survival periods," explained Huang Huiqiang. "While approximately 70% of patients achieve long-term disease-free survival through frontline therapies, about 30% face poor prognoses, relapse, or resistance to standard treatments. In such cases, CAR-T therapy emerges as a critical option, providing hope for patients ineligible for transplantation or unresponsive to prior therapies."
Sun Yat-sen University Cancer Center plans to further explore innovative applications of CAR-T therapy in clinical research.
15/04/2025
China hospital has achieved complete remission in a lymphoma patient who relapsed after 5th-line chemotherapy through CAR-T cell therapy. Recently, a patient with relapsed lymphoma after 5th-line chemotherapy achieved complete remission for over two years through CAR-T therapy, marking one of the longest survivors following the approval of China's first commercially available CAR-T treatment. This milestone was achieved by a team led by Professor Huang Huiqiang at Sun Yat-sen University Cancer Center.
Lymphoma is a common hematologic malignancy, traditionally treated with combined chemotherapy regimens, autologous hematopoietic stem cell transplantation, targeted therapy, and immunomodulatory agents. CAR-T (Chimeric Antigen Receptor T-cell) therapy, a cutting-edge precision oncology approach, has recently transitioned from experimental to clinical practice, offering rapid and highly effective treatment outcomes.
"Diffuse large B-cell lymphoma (DLBCL), a prevalent aggressive lymphoma, is characterized by rapid progression, high mortality, and short survival periods," explained Huang Huiqiang. "While approximately 70% of patients achieve long-term disease-free survival through frontline therapies, about 30% face poor prognoses, relapse, or resistance to standard treatments. In such cases, CAR-T therapy emerges as a critical option, providing hope for patients ineligible for transplantation or unresponsive to prior therapies."
Sun Yat-sen University Cancer Center plans to further explore innovative applications of CAR-T therapy in clinical research.
Be the first to know and let us send you an email when Advanced Medicine in China posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
While CAR-T cell therapy was initially developed in the USA, it has quickly spread to the rest of the world. With more than 4 million people diagnosed with cancer each year, China has been particularly fast to adopt this concept and today it runs nearly as many CAR-T trials as the USA.
From a target perspective, not everything is so rosy though. The leading CAR-T program for most Chinese biotechs targets CD19 to direct T cells to cancer cells, already approved for Novartis and Kite Pharma in the USA and Europe. So this is a case of replicating rather than disruptive innovation. Although, it is better not to generalize: Nanjing Legend Biotech surprised recently with a deal with Johnson & Johnson to co-develop one of the most advanced BCMA-targeted CAR-T therapies, including a $350M upfront fee. EPVantage makes a good review of the upcoming BCMA CAR-T therapies.
Here are some examples of the leading cell therapy innovators in China:
Innovative Cellular Therapeutics (ICT), Shanghai. ICT is combining stem cells, gene editing, gene therapy and CAR technologies to develop cancer treatments. They have one of the largest pipelines of cell therapies under development and some of the treatments closest to be approved in China and reach patients with blood cancers.
Cellular Biomedicine Group (CBMG), Shanghai, Beijing and Hong Kong. Founded in 2001, CBMG is already developing nine CAR-T therapies, some of them including additional improvements such as the ability to recognize multiple cancer markers or antigens. In 2015 they significantly increased their capabilities when they partner with the Chinese PLA General Hospital, one of the front runner CAR-T academic institutions in China. Additionally, they are also developing stem cell and cancer vaccine therapies.
CARsgen Therapeutics, Shanghai. Compared with CBMG, CARsgene may seem as a newcomer, only funded in October 2014. However, they partnered with the leading cancer research centers in Shanghai and licensed six CAR-T already in clinical development. Additionally, they are developing multiple innovations with their collaborators, such as logic-CAR to enable a better control of the immune response towards cancer cells.
PersonGen Biomedicine, Suzhou. In addition to develop CAR-T cell therapies, PersonGen is also working on CAR-NK, an approach that could enhance the patients’ innate immunity to fight cancer. They are pioneering this space with the most advanced CAR-NK therapies.
Hebei Senlang Biotech, Shijiazhuang. Hebei Senlang is developing therapies utilizing two mechanisms to direct the immune system towards cancer cells: CAR and TCR technologies. While CAR has shown the best results in blood cancers, TCR could be better suited for solid tumors. They already have eight therapies under development.
Interestingly, when two of the American pioneers in CAR-T therapies, Juno Therapeutics (now part of Celgene) and Kite Pharma (now part of Gylead), decided to expand their operations to China they partnered with local companies, acknowledging the need to understand the Chinese regulatory and commercial environment to succeed. Juno formed a joint-venture with WuXi AppTec (JW Therapeutics) and Kite a joint-venture with Fosun Pharmaceutical (Fosun Pharma Kite Biotechnology).
